• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中度至重度小儿哮喘中皮质类固醇吸入器类型与唾液微生物群的关联

Association of Corticosteroid Inhaler Type with Saliva Microbiome in Moderate-to-Severe Pediatric Asthma.

作者信息

Alizadeh Bahmani Amir Hossein, Abdel-Aziz Mahmoud I, Hashimoto Simone, Bang Corinna, Brandstetter Susanne, Corcuera-Elosegui Paula, Franke Andre, Gorenjak Mario, Harner Susanne, Kheiroddin Parastoo, López-Fernández Leyre, Neerincx Anne H, Pino-Yanes Maria, Potočnik Uroš, Sardón-Prado Olaia, Toncheva Antoaneta A, Wolff Christine, Kabesch Michael, Kraneveld Aletta D, Vijverberg Susanne J H, Maitland-van der Zee Anke H

机构信息

Department of Pulmonary Medicine, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

Amsterdam Institute for Infection and Immunity, Inflammatory Diseases, 1105 AZ Amsterdam, The Netherlands.

出版信息

Biomedicines. 2025 Jan 2;13(1):89. doi: 10.3390/biomedicines13010089.

DOI:10.3390/biomedicines13010089
PMID:39857673
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11761874/
Abstract

: Metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) are common inhaled corticosteroid (ICS) inhaler devices. The difference in formulation and administration technique of these devices may influence oral cavity microbiota composition. We aimed to compare the saliva microbiome in children with moderate-to-severe asthma using ICS via MDIs versus DPIs. : Saliva samples collected from 143 children (6-17 yrs) with moderate-to-severe asthma across four European countries (The Netherlands, Germany, Spain, and Slovenia) as part of the SysPharmPediA cohort were subjected to 16S rRNA sequencing. The microbiome was compared using global diversity (α and β) between two groups of participants based on inhaler devices (MDI (n = 77) and DPI (n = 65)), and differential abundance was compared using the Analysis of Compositions of Microbiomes with the Bias Correction (ANCOM-BC) method. : No significant difference was observed in α-diversity between the two groups. However, β-diversity analysis revealed significant differences between groups using both Bray-Curtis and weighted UniFrac methods (adjusted -value = 0.015 and 0.044, respectively). Significant differential abundance between groups, with higher relative abundance in the MDI group compared to the DPI group, was detected at the family level [Carnobacteriaceae (adjusted = 0.033)] and at the genus level [ (adjusted = 0.021) and (adjusted = 0.011)]. : Types of ICS devices are associated with different saliva microbiome compositions in moderate-to-severe pediatric asthma. The causal relation between inhaler types and changes in saliva microbiota composition needs to be further evaluated, as well as whether this leads to different potential adverse effects in terms of occurrence and level of severity.

摘要

定量吸入器(MDIs)和干粉吸入器(DPIs)是常见的吸入性糖皮质激素(ICS)吸入装置。这些装置在制剂和给药技术上的差异可能会影响口腔微生物群的组成。我们旨在比较中度至重度哮喘儿童使用MDIs与DPIs吸入ICS时的唾液微生物群。

作为SysPharmPediA队列研究的一部分,从四个欧洲国家(荷兰、德国、西班牙和斯洛文尼亚)的143名6至17岁中度至重度哮喘儿童中收集唾液样本,并进行16S rRNA测序。根据吸入装置(MDI组n = 77,DPI组n = 65),使用全局多样性(α和β)对两组参与者的微生物群进行比较,并使用带偏差校正的微生物群组成分析(ANCOM-BC)方法比较差异丰度。

两组之间在α多样性上未观察到显著差异。然而,β多样性分析显示,使用Bray-Curtis和加权UniFrac方法时,两组之间存在显著差异(校正P值分别为0.015和0.044)。在科水平上[肉杆菌科(校正P = 0.033)]和属水平上[某属(校正P = 0.021)和另一属(校正P = 0.011)]检测到两组之间存在显著的差异丰度,MDI组的相对丰度高于DPI组。

在中度至重度儿童哮喘中,ICS装置类型与不同的唾液微生物群组成相关。吸入器类型与唾液微生物群组成变化之间的因果关系需要进一步评估,以及这是否会导致在发生和严重程度方面不同的潜在不良反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f4/11761874/a74b1d0304f7/biomedicines-13-00089-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f4/11761874/009bb3f18fd7/biomedicines-13-00089-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f4/11761874/e1f3709eb8e8/biomedicines-13-00089-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f4/11761874/ae4fa0931492/biomedicines-13-00089-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f4/11761874/a74b1d0304f7/biomedicines-13-00089-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f4/11761874/009bb3f18fd7/biomedicines-13-00089-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f4/11761874/e1f3709eb8e8/biomedicines-13-00089-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f4/11761874/ae4fa0931492/biomedicines-13-00089-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04f4/11761874/a74b1d0304f7/biomedicines-13-00089-g004.jpg

相似文献

1
Association of Corticosteroid Inhaler Type with Saliva Microbiome in Moderate-to-Severe Pediatric Asthma.中度至重度小儿哮喘中皮质类固醇吸入器类型与唾液微生物群的关联
Biomedicines. 2025 Jan 2;13(1):89. doi: 10.3390/biomedicines13010089.
2
Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.不同吸入性糖皮质激素及其与长效β2受体激动剂联合使用治疗12岁及以上成人和儿童慢性哮喘比较效果的系统评价与经济学分析
Health Technol Assess. 2008 May;12(19):iii-iv, 1-360. doi: 10.3310/hta12190.
3
Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study.基层医疗中哮喘管理使用皮质类固醇吸入器装置的成本效益分析:一项真实世界观察性研究。
Clinicoecon Outcomes Res. 2010;2:75-85. doi: 10.2147/ceor.s10835. Epub 2010 Jul 1.
4
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.吸入装置在哮喘和慢性阻塞性气道疾病中的有效性比较:文献系统评价
Health Technol Assess. 2001;5(26):1-149. doi: 10.3310/hta5260.
5
Inhaler device, administration technique, and adherence to inhaled corticosteroids in patients with asthma.哮喘患者使用吸入器装置、给药技术及吸入性糖皮质激素的依从性
Prim Care Respir J. 2011 Jun;20(2):148-54. doi: 10.4104/pcrj.2011.00022.
6
Which inhaled corticosteroid and long-acting β-agonist combination is better in patients with moderate-to-severe asthma, a dry powder inhaler or a pressurized metered-dose inhaler?对于中重度哮喘患者,哪种吸入性糖皮质激素与长效β受体激动剂的组合更好,是干粉吸入器还是压力定量吸入器?
Drug Deliv. 2017 Nov;24(1):1395-1400. doi: 10.1080/10717544.2017.1378937.
7
Comparative analysis of real-world data on the efficacy and safety of and adherence to ICS/LABA combinations in asthma management.哮喘管理中吸入性糖皮质激素/长效β2受体激动剂联合制剂疗效、安全性及依从性的真实世界数据对比分析
Respir Res. 2025 Jan 13;26(1):12. doi: 10.1186/s12931-024-03084-7.
8
A prospective study of switching asthma patients from a Fixed-Dose Combination (FDC) Inhaled Corticosteroid [ICS]/Long-Acting Beta Agonist [LABA] therapy delivered by Dry Powder Inhaler (DPI) to ICS/LABA delivered by pressurised Metered Dose Inhaler (pMDI).一项将干粉吸入器(DPI)输送的固定剂量组合(FDC)吸入皮质类固醇[ICS]/长效β激动剂[LABA]治疗的哮喘患者转换为压力计量吸入器(pMDI)输送的ICS/LABA 的前瞻性研究。
Respir Med. 2022 Apr;194:106771. doi: 10.1016/j.rmed.2022.106771. Epub 2022 Feb 12.
9
Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation.吸入性皮质类固醇和长效β2-激动剂固定组合治疗患者的哮喘控制情况。一项真实世界研究比较干粉吸入器和压力定量气雾剂超细配方。
BMC Pulm Med. 2011 Jul 15;11:40. doi: 10.1186/1471-2466-11-40.
10
Concurrent use of metered-dose and dry powder inhalers by children with persistent asthma does not adversely affect spacer/inhaler technique.持续性哮喘儿童同时使用定量吸入器和干粉吸入器不会对储雾罐/吸入器技术产生不利影响。
Ann Pharmacother. 2006 Oct;40(10):1743-6. doi: 10.1345/aph.1G306. Epub 2006 Sep 12.

本文引用的文献

1
Early-Life Exposure to Air Pollution and Childhood Asthma Cumulative Incidence in the ECHO CREW Consortium.早期暴露于空气污染与 ECHO CREW 联盟儿童哮喘累积发病率。
JAMA Netw Open. 2024 Feb 5;7(2):e240535. doi: 10.1001/jamanetworkopen.2024.0535.
2
Lung microbiome: new insights into the pathogenesis of respiratory diseases.肺部微生物组:呼吸系统疾病发病机制的新见解。
Signal Transduct Target Ther. 2024 Jan 17;9(1):19. doi: 10.1038/s41392-023-01722-y.
3
Role of Air Pollution in the Development of Asthma Among Children with a History of Bronchiolitis in Infancy.
空气污染在婴儿期毛细支气管炎史患儿哮喘发展中的作用。
Epidemiology. 2023 Jul 1;34(4):554-564. doi: 10.1097/EDE.0000000000001613. Epub 2023 Apr 11.
4
Classifying asthma control using salivary and fecal bacterial microbiome in children with moderate-to-severe asthma.利用唾液和粪便细菌微生物群对中重度哮喘儿童的哮喘控制情况进行分类。
Pediatr Allergy Immunol. 2023 Feb;34(2):e13919. doi: 10.1111/pai.13919.
5
Medication use in uncontrolled pediatric asthma: Results from the SysPharmPediA study.儿童哮喘未控制患者的药物使用情况:SysPharmPediA 研究结果。
Eur J Pharm Sci. 2023 Feb 1;181:106360. doi: 10.1016/j.ejps.2022.106360. Epub 2022 Dec 13.
6
The upper-airway microbiome as a biomarker of asthma exacerbations despite inhaled corticosteroid treatment.尽管使用了吸入性糖皮质激素治疗,但上呼吸道微生物群作为哮喘急性加重的生物标志物。
J Allergy Clin Immunol. 2023 Mar;151(3):706-715. doi: 10.1016/j.jaci.2022.09.041. Epub 2022 Nov 4.
7
Recent advances in the treatment of childhood asthma: a clinical pharmacology perspective.儿童哮喘治疗的最新进展:临床药理学视角。
Expert Rev Clin Pharmacol. 2022 Oct;15(10):1165-1176. doi: 10.1080/17512433.2022.2131537. Epub 2022 Oct 6.
8
Effect of inhaled corticosteroids on microbiome and microbial correlations in asthma over a 9-month period.吸入性皮质类固醇对哮喘患者微生物组及其相关性的影响:为期 9 个月的研究
Clin Transl Sci. 2022 Jul;15(7):1723-1736. doi: 10.1111/cts.13288. Epub 2022 May 23.
9
A System Pharmacology Multi-Omics Approach toward Uncontrolled Pediatric Asthma.一种针对儿童难治性哮喘的系统药理学多组学方法。
J Pers Med. 2021 May 28;11(6):484. doi: 10.3390/jpm11060484.
10
The Effects of Corticosteroids on the Respiratory Microbiome: A Systematic Review.皮质类固醇对呼吸道微生物群的影响:一项系统综述。
Front Med (Lausanne). 2021 Mar 10;8:588584. doi: 10.3389/fmed.2021.588584. eCollection 2021.